AstraZeneca PLC (AZN) Seeks Partner For Potential $5 Billion Alzheimer's Blockbuster
5/7/2014 8:08:34 AM
AstraZeneca, fighting a $106 billion bid approach from Pfizer, is talking to other companies as it seeks a partnering deal for its experimental Alzheimer's drug. Briggs Morrison, global head of medicines development, said AstraZeneca was talking to companies with more experience of Alzheimer's about a deal to share development of its so-called BACE inhibitor drug, which is set to enter late-stage Phase III development. A deal to share Phase III costs and share eventual profits was probably the easiest approach, he told reporters on Wednesday, but AstraZeneca could also out-license the product and take a royalty on any eventual sales.
Help employers find you! Check out all the jobs and post your resume.
comments powered by